Wealth Effects LLC Has $189,000 Holdings in ImmunityBio, Inc. (NASDAQ:IBRX)

Wealth Effects LLC lowered its position in ImmunityBio, Inc. (NASDAQ:IBRX) by 18.6% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 73,700 shares of the company’s stock after selling 16,800 shares during the period. Wealth Effects LLC’s holdings in ImmunityBio were worth $189,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. Captrust Financial Advisors bought a new stake in shares of ImmunityBio in the 3rd quarter valued at $41,000. Mutual Advisors LLC acquired a new position in ImmunityBio during the 4th quarter worth approximately $41,000. Virtu Financial LLC bought a new position in ImmunityBio in the third quarter worth approximately $51,000. Algert Global LLC acquired a new stake in ImmunityBio in the second quarter valued at approximately $86,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of ImmunityBio by 22.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock valued at $99,000 after acquiring an additional 4,545 shares in the last quarter. Institutional investors own 8.58% of the company’s stock.

ImmunityBio Stock Down 1.6 %

IBRX opened at $3.08 on Wednesday. ImmunityBio, Inc. has a 1 year low of $2.28 and a 1 year high of $10.53. The firm’s fifty day moving average price is $3.43 and its two-hundred day moving average price is $4.03.

Wall Street Analyst Weigh In

Several research firms recently issued reports on IBRX. BTIG Research started coverage on shares of ImmunityBio in a research report on Friday, January 10th. They issued a “buy” rating and a $6.00 price target for the company. D. Boral Capital reissued a “buy” rating and set a $30.00 target price on shares of ImmunityBio in a research report on Monday. Finally, EF Hutton Acquisition Co. I raised shares of ImmunityBio to a “strong-buy” rating in a research report on Wednesday, October 23rd.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.